BIOMAT Database Logo BIOMAT Database Logo

[Synergistic activity of isepamicin and beta-lactam antibiotics against Pseudomonas aeruginosa in vitro and in vivo]. 1988

Y Shiritani, and S Yamaji, and A Aoki, and M Saigusa, and S Yokoiyama, and S Gato, and A Tsuji
Research Laboratories, Toyo Jozo Co., Ltd.

Synergistic activities of isepamicin (ISP) and a beta-lactam antibiotic such as piperacillin (PIPC) or cefotaxime (CTX) against Pseudomonas aeruginosa were demonstrated in vitro and in vivo. In vitro synergistic activity was observed when ISP was used together PIPC or CTX. The synergy observed in vitro was reproduced in vivo against experimental mouse infections, and a ISP-PIPC or a ISP-CTX combination showed significantly greater protective effects than individual antibiotics by themselves.

UI MeSH Term Description Entries
D008297 Male Males
D008813 Mice, Inbred ICR An inbred strain of mouse that is used as a general purpose research strain, for therapeutic drug testing, and for the genetic analysis of CARCINOGEN-induced COLON CANCER. Mice, Inbred ICRC,Mice, ICR,Mouse, ICR,Mouse, Inbred ICR,Mouse, Inbred ICRC,ICR Mice,ICR Mice, Inbred,ICR Mouse,ICR Mouse, Inbred,ICRC Mice, Inbred,ICRC Mouse, Inbred,Inbred ICR Mice,Inbred ICR Mouse,Inbred ICRC Mice,Inbred ICRC Mouse
D010538 Peritonitis INFLAMMATION of the PERITONEUM lining the ABDOMINAL CAVITY as the result of infectious, autoimmune, or chemical processes. Primary peritonitis is due to infection of the PERITONEAL CAVITY via hematogenous or lymphatic spread and without intra-abdominal source. Secondary peritonitis arises from the ABDOMINAL CAVITY itself through RUPTURE or ABSCESS of intra-abdominal organs. Primary Peritonitis,Secondary Peritonitis,Peritonitis, Primary,Peritonitis, Secondary
D010878 Piperacillin Semisynthetic, broad-spectrum, AMPICILLIN derived ureidopenicillin antibiotic proposed for PSEUDOMONAS infections. It is also used in combination with other antibiotics. AB-Piperacillin,Cl-227193,Pipcil,Pipera-Hameln,Piperacillin Curasan,Piperacillin Fresenius,Piperacillin Hexal,Piperacillin Monosodium Salt,Piperacillin Sodium,Piperacillin-Ratiopharm,Pipercillin,Pipracil,Pipril,T-1220,T1220,AB Piperacillin,Cl 227193,Cl227193,Curasan, Piperacillin,Monosodium Salt, Piperacillin,Pipera Hameln,Piperacillin Ratiopharm,Salt, Piperacillin Monosodium,Sodium, Piperacillin,T 1220
D011550 Pseudomonas aeruginosa A species of gram-negative, aerobic, rod-shaped bacteria commonly isolated from clinical specimens (wound, burn, and urinary tract infections). It is also found widely distributed in soil and water. P. aeruginosa is a major agent of nosocomial infection. Bacillus aeruginosus,Bacillus pyocyaneus,Bacterium aeruginosum,Bacterium pyocyaneum,Micrococcus pyocyaneus,Pseudomonas polycolor,Pseudomonas pyocyanea
D011552 Pseudomonas Infections Infections with bacteria of the genus PSEUDOMONAS. Infections, Pseudomonas,Pseudomonas aeruginosa Infection,Infection, Pseudomonas,Pseudomonas Infection,Pseudomonas aeruginosa Infections
D012141 Respiratory Tract Infections Invasion of the host RESPIRATORY SYSTEM by microorganisms, usually leading to pathological processes or diseases. Respiratory System Infections,Upper Respiratory Tract Infection,Upper Respiratory Tract Infections,Infections, Respiratory,Infections, Respiratory Tract,Infections, Upper Respiratory,Infections, Upper Respiratory Tract,Respiratory Infections,Upper Respiratory Infections,Infection, Respiratory System,Infection, Respiratory Tract,Respiratory Infection, Upper,Respiratory System Infection,Respiratory Tract Infection
D002439 Cefotaxime Semisynthetic broad-spectrum cephalosporin. Benaxima,Biosint,Cefotaxim,Cefotaxime Sodium,Cefradil,Cephotaxim,Claforan,Fotexina,HR-756,Kendrick,Klaforan,Primafen,Ru-24756,Taporin,HR 756,HR756,Ru 24756,Ru24756,Sodium, Cefotaxime
D004357 Drug Synergism The action of a drug in promoting or enhancing the effectiveness of another drug. Drug Potentiation,Drug Augmentation,Augmentation, Drug,Augmentations, Drug,Drug Augmentations,Drug Potentiations,Drug Synergisms,Potentiation, Drug,Potentiations, Drug,Synergism, Drug,Synergisms, Drug
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug

Related Publications

Y Shiritani, and S Yamaji, and A Aoki, and M Saigusa, and S Yokoiyama, and S Gato, and A Tsuji
Synergistic activity of astromicin and beta-lactam antibiotics against Pseudomonas aeruginosa in vitro and in vivo.
December 1984, The Journal of antibiotics,
Y Shiritani, and S Yamaji, and A Aoki, and M Saigusa, and S Yokoiyama, and S Gato, and A Tsuji
[In vitro combination effects of astromicin and beta-lactam antibiotics against Pseudomonas aeruginosa. In vitro synergistic activities].
April 1985, The Japanese journal of antibiotics,
Y Shiritani, and S Yamaji, and A Aoki, and M Saigusa, and S Yokoiyama, and S Gato, and A Tsuji
Synergistic activities of fortimicin A and beta-lactam antibiotics against Pseudomonas aeruginosa.
July 1981, Antimicrobial agents and chemotherapy,
Y Shiritani, and S Yamaji, and A Aoki, and M Saigusa, and S Yokoiyama, and S Gato, and A Tsuji
Comparative in vitro activity of aztreonam, other beta-lactam antibiotics and aminoglycosides against Pseudomonas aeruginosa.
August 1984, Chemioterapia : international journal of the Mediterranean Society of Chemotherapy,
Y Shiritani, and S Yamaji, and A Aoki, and M Saigusa, and S Yokoiyama, and S Gato, and A Tsuji
[In vitro combination effects of astromicin and beta-lactam antibiotics against CFS-sensitive and CFS-resistant Pseudomonas aeruginosa. In vitro synergistic activity].
May 1988, The Japanese journal of antibiotics,
Y Shiritani, and S Yamaji, and A Aoki, and M Saigusa, and S Yokoiyama, and S Gato, and A Tsuji
[In vivo combination effects of astromicin and beta-lactam antibiotics against Pseudomonas aeruginosa].
June 1986, The Japanese journal of antibiotics,
Y Shiritani, and S Yamaji, and A Aoki, and M Saigusa, and S Yokoiyama, and S Gato, and A Tsuji
In vitro activity of ceftazidime and other beta-lactam antibiotics against nosocomial strains of Pseudomonas aeruginosa.
January 1984, The Journal of international medical research,
Y Shiritani, and S Yamaji, and A Aoki, and M Saigusa, and S Yokoiyama, and S Gato, and A Tsuji
[Effects of isepamicin and beta-lactam antibiotics on the release of endotoxin from Pseudomonas aeruginosa].
January 1999, The Japanese journal of antibiotics,
Y Shiritani, and S Yamaji, and A Aoki, and M Saigusa, and S Yokoiyama, and S Gato, and A Tsuji
beta-Lactamases of Pseudomonas aeruginosa and susceptibility against beta-lactam antibiotics.
February 1985, Chemioterapia : international journal of the Mediterranean Society of Chemotherapy,
Y Shiritani, and S Yamaji, and A Aoki, and M Saigusa, and S Yokoiyama, and S Gato, and A Tsuji
Specific phospholipids enhance the activity of beta-lactam antibiotics against Pseudomonas aeruginosa.
September 2000, The Journal of antimicrobial chemotherapy,
Copied contents to your clipboard!